Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection

Inclusion Criteria: * 25 pregnant women with HBeAg (+), HBV DNA ≥ 2\*10\^6IU/mL who met the diagnostic criteria in the guidelines for the prevention and treatment of chronic hepatitis B were pregnant women at 24-28 weeks of pregnancy. * 25 non-pregnant women with HBeAg (+), HBV DNA ≥ 2\*10\^6IU/mL who met the diagnostic criteria in the guidelines for the prevention and treatment of chronic hepatitis B. * The enrolled patients were all newly admitted patients without treatment, and if they did not meet the standard after completing the relevant examination, they would be removed. Exclusion Criteria: * Coinfection with HAV, HCV, HDV, HEV or HIV; * A history of antiviral therapy or concurrent treatment with immunoregulatory drugs, antitumor drugs, cytotoxic drugs or immunosuppressive steroids; * Three-dimensional ultrasonography showed fetal malformation; * The spouse is infected with HBV; * History of decompensated liver disease (e.g., decompensated liver disease with coagulation disorders, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia, ascites and esophageal varicose bleeding), history of liver cancer or other chronic liver disease (e.g., autoimmune hepatitis) or clinical symptoms; * History of immune diseases; * A history of serious cardiovascular disease; * Other reasons the researchers considered it inappropriate to participate in the trial.